INSULIN LEVELS AND FIBRINOLYTIC-ACTIVITY IN PATIENTS WITH END-STAGE RENAL-DISEASE

被引:14
作者
HONG, SY
YANG, DH
机构
[1] Department of Internal Medicine, Soonchunhyang University Hospital, 330-100 Chunan City, Chungnam
来源
NEPHRON | 1994年 / 68卷 / 03期
关键词
END-STAGE RENAL DISEASE; INSULIN; PAI-1; CONCENTRATION; FIBRINOLYTIC ACTIVITY;
D O I
10.1159/000188395
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Considering that PAI-1 is an important factor modulating the systemic fibrinolytic activity, the abnormal insulin metabolism frequently seen in end-stage renal disease (ESRD) may cause decreased fibrinolytic activity in concert with PAI-1. To study this possibility, we measured insulin levels and compared it with the fibrinolytic profiles in ESRD patients. Fasting blood sugar, insulin, and C peptide levels were higher in ESRD patients than in the control group. In the ESRD patients, the insulin levels showed a positive correlation with C peptide (r=0.612, p=0.0001), fasting blood sugar (r=0.334, p=0.044), and PAI-1 antigen (r=0.474, p=0.0001) and a reverse correlation with euglobulin fibrinolytic activity (r=0.5, p=0.005), but no correlation with t-PA antigen. The euglobulin fibrinolytic activity showed a reverse correlation with PAI-1 antigen (r=0.289, p=0.0144), but no correlation with t-PA antigen. Our results suggest that abnormal insulin metabolism and/or insulin resistance, which occur frequently in ESRD, may play an important role in the decrease in systemic fibrinolytic activity by the regulation of the PAI-1 concentration.
引用
收藏
页码:329 / 333
页数:5
相关论文
共 36 条
[1]  
ALESSI MC, 1988, THROMB HAEMOSTASIS, V60, P491
[2]  
COLE E, 1978, PROGR CHEM FIBRINOLY, V3, P99
[3]   GENERATION IN PLASMA OF A FAST-ACTING INHIBITOR OF PLASMINOGEN-ACTIVATOR IN RESPONSE TO ENDOTOXIN STIMULATION [J].
COLUCCI, M ;
PARAMO, JA ;
COLLEN, D .
JOURNAL OF CLINICAL INVESTIGATION, 1985, 75 (03) :818-824
[4]  
DOSNE A M, 1987, Fibrinolysis, V1, P45, DOI 10.1016/0268-9499(87)90032-4
[5]   INTERLEUKIN-1 AND LIPOPOLYSACCHARIDE INDUCE AN INHIBITOR OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR INVIVO AND IN CULTURED ENDOTHELIAL-CELLS [J].
EMEIS, JJ ;
KOOISTRA, T .
JOURNAL OF EXPERIMENTAL MEDICINE, 1986, 163 (05) :1260-1266
[6]   THE PRIMARY PLASMINOGEN-ACTIVATOR INHIBITORS IN ENDOTHELIAL-CELLS, PLATELETS, SERUM, AND PLASMA ARE IMMUNOLOGICALLY RELATED [J].
ERICKSON, LA ;
HEKMAN, CM ;
LOSKUTOFF, DJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1985, 82 (24) :8710-8714
[7]   SHORT-TERM INFUSIONS OF INSULIN, TRIACYLGLYCEROL AND GLUCOSE DO NOT CAUSE ACUTE INCREASES IN PLASMINOGEN-ACTIVATOR INHIBITOR-1 CONCENTRATIONS IN MAN [J].
GRANT, PJ ;
KRUITHOF, EKO ;
FELLEY, CP ;
FELBER, JP ;
BACHMANN, F .
CLINICAL SCIENCE, 1990, 79 (05) :513-516
[8]  
HAMSTEN A, 1987, LANCET, V2, P3
[9]   INCREASED PLASMA-LEVELS OF A RAPID INHIBITOR OF TISSUE PLASMINOGEN-ACTIVATOR IN YOUNG SURVIVORS OF MYOCARDIAL-INFARCTION [J].
HAMSTEN, A ;
WIMAN, B ;
DEFAIRE, U ;
BLOMBACK, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1985, 313 (25) :1557-1563
[10]  
HONG SY, 1993, NEPHRON, V63, P188